Altor, MRA to jointly sponsor studies of ALT-803 against metastatic melanoma

MRA funds the project led by Dr Kim Margolis at the University of Washington in collaboration with Altor, under its Academic-Industry Partnership grant program.

The effects of ALT-803 on the immune system will also be investigated under the project.

Altor CEO Hing Wong said, "We are very pleased that MRA recognizes the potential of ALT-803 as a curative treatment for melanoma."

"Altor’s IL-15 technology programs have also received funding in the form of two Small Business Innovation Research grants from the National Cancer Institute and a James & Esther King Biomedical Research Grant, awarded by Florida’s Department of Health, to Altor’s collaborators at the MD Anderson Cancer Center, Orlando," Wong added.